Navigation Links
Nile Therapeutics Reports 2010 Second Quarter Financial Results

r the year ended December 31, 2009 filed with the Securities and Exchange Commission on March 3, 2010. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.Condensed Statement of Operations(unaudited)Three months ended June 30,Six months ended June 30,Period fromAugust 1, 2005 (inception)2010200920102009through June 30, 2010Grant income

482,235Operating expenses:Research and development

1,055,7591,103,4282,369,1812,428,03224,147,236General and administrative

445,4481,397,6891,068,6501,860,15713,065,412Total operating expenses

1,501,2072,501,1173,437,8314,288,18937,212,648Loss from operations

(1,501,207)(2,501,117)(3,437,831)(4,288,189)(36,730,413)Other income (expense):Interest income

6,7265,88611,57220,573779,154Interest expense

----(1,273,734)Other expense

(40)(4,859)(82)(11,282)(100,051)Total other income (expense)

6,6861,02711,4909,291(594,631)Net loss

(37,325,044)Basic and diluted loss per share

(0.18)Weighted-average common shares outstanding

32,285,82424,149,40529,700,18924,149,405Summary Balance Sheet Data(in thousands)June 30, 2010

December 31, 2009(unaudited)Cash and cash equivalents


3,176Total assets


3,620Stockholders' equity



SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
(Date:9/16/2014)... 2014 A study led by St. ... chemotherapy dose threshold below which male childhood cancer survivors ... appears in September 17 edition of the journal ... are at highest risk for reduced sperm production as ... of pre-treatment fertility preservation methods such as sperm banking. ...
(Date:9/16/2014)... Ill. , Sept. 16, 2014 ... new director of Business Communications & Advocacy, Urology ... President, Business Communications & Advocacy Margaret Long. In this ... commitment to urology to patient and advocacy organizations, ... teams on key strategic initiatives. Noland,s appointment is ...
(Date:9/16/2014)... , Sept. 16, 2014 /PRNewswire-iReach/ -- Dan ... GWM Products, LLC, manufacturer of the RTD ® ... plan to expand its sales presence in the U.S. ... hiring and training direct field sales representatives in new ... The company plans to add up to 20 sales ...
Breaking Medicine Technology:Improved risk identification will aid fertility preservation in young male cancer patients 2Improved risk identification will aid fertility preservation in young male cancer patients 3Improved risk identification will aid fertility preservation in young male cancer patients 4Christy Noland to Lead Urology Advocacy and Communications for Astellas 2GWM Products, LLC, announces U.S. market expansion. Dan York added as Director of Sales as part of nationwide growth initiative. 2
... Va., Oct. 30 CEL-SCI Corporation,(Amex: CVM ) ... at the Rodman & Renshaw 9th Annual Healthcare Conference ... 5-7, 2007. The presentation,will be focused on its Phase ... product seeking to become a new first line standard ...
... the Potential ... INDIANAPOLIS and MUMBAI, India, Oct. 30 Eli,Lilly and Company ... into an,agreement with Glenmark Pharmaceuticals S.A. (GPSA) a wholly owned,subsidiary ... agreement, Lilly will acquire the rights to a portfolio of ...
Cached Medicine Technology:CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference 2Lilly and Glenmark Pharmaceuticals Announce License Agreement 2Lilly and Glenmark Pharmaceuticals Announce License Agreement 3Lilly and Glenmark Pharmaceuticals Announce License Agreement 4Lilly and Glenmark Pharmaceuticals Announce License Agreement 5
(Date:9/17/2014)... ATLANTA, GA (PRWEB) September 17, 2014 ... Contact Center software, has launched Presence Suite 10.0, ... journey and improve the customer experience. , The ... autonomy and flexibility. Now supervisors can get a ... and understand who is contributing most and who ...
(Date:9/16/2014)... 17, 2014 Recently,, the popular ... new assortment of strand woven bamboo floors ... launched a big promotion for the new items; the ... , Autumn is a great shopping season. Therefore, ... old and new customers. All practical items offered by ...
(Date:9/16/2014)... (PRWEB) September 17, 2014 Dog Food ... dog owners the true poisonous ingredients in most commercial dog ... recipes has caught the attention of Shane Michaels, prompting an ... just as much of a family member as any other ... dog dies earlier than it should due to poor diet” ...
(Date:9/16/2014)... Retinol is favored by a majority of dermatologists and ... so many benefits - it is one of those amazing ... Sublime Beauty . "Healthy skin is our goal, and Retinol ... Retinol Serum with Vitamin C is a non-irritating, silky serum ... Retinol Serum with Vitamin C is now 30% ...
(Date:9/16/2014)... City, UT (PRWEB) September 16, 2014 ... Benefits Solution, published new information on transitioning employees ... Zane Benefits, with the Affordable Care Act (ACA) ... businesses will be steering some or all of ... as no surprise. With guaranteed issue plans, coverage ...
Breaking Medicine News(10 mins):Health News:Presence Technology’s 10.0 Release Drives Contact Center Web Supervisor Effectiveness While Reducing Operation Costs and Delivering Enterprise Grade Scalability 2Health Announces Its Promotion For Strand Woven Bamboo Floors 2Health News:Dog Food Secrets: Review Exposes Andrew Lewis’ Guide to Happier, Healthier Dogs with Homemade Dog Food 2Health News:Retinol, the Gold Standard in Skin Care, Available in a Serum with Vitamin C from Sublime Beauty®; Now 30% Off 2Health News:Zane Benefits Publishes New Information on Transitioning Employees to Individual Health Insurance 2
... Walk on the Capitol,is proud to announce Caitlin Van ... guest speaker for our National obesity awareness event,in Washington, ... Capitol is a,history-making awareness event that will gather thousands ... the obesity epidemic and,the need for expanded efforts in ...
... 2 ,Dawning Technologies, Inc. (Dawning) and Medical Automation ... joint project to leverage their,product synergies and create ... project will focus on the seamless integration of ... RALS(R)-,Plus POC Data Management solutions. RALS-Plus is a ...
... Merger, CHICAGO, June 2 Allscripts, the ... that,physicians use to improve healthcare, announced today that ... Act of,1976, with respect to the merger agreement ... Healthcare to form Allscripts-Misys Healthcare,Solutions, Inc., has expired., ...
... MONTREAL, June 2 /PRNewswire-FirstCall/ - Haemacure ... company developing,high-value human plasma-derived protein products for ... quarter results., Financing, As a ... to-date from key,shareholders to exercise their Series ...
... care deserves more funding for estimated 2.5 million displaced ... removed from their homes due to mistreatment have fewer ... kinship care -- than if they,re placed in foster ... by researchers at Children,s Hospital of Philadelphia, looked at ...
... are similar to the type diagnosed in Sen. Edward ... experimental cancer vaccine is showing promise against the same ... Kennedy, researchers are reporting. , The vaccine, when given ... with glioblastoma multiforme tumors. Kennedy was diagnosed last month ...
Cached Medicine News:Health News:Television Star Caitlin Van Zandt Signs-on as Special Guest Speaker for National Obesity Awareness Event in Washington, DC, on June 17 2Health News:Dawning Technologies, Inc. and Medical Automation Systems, Inc. to Develop a Business Partnership 2Health News:Antitrust Waiting Period Expires on Allscripts-Misys Merger Agreement 2Health News:Haemacure Reports on Financing Progress and Second Quarter Results 2Health News:Haemacure Reports on Financing Progress and Second Quarter Results 3Health News:Kids Living With Relatives Have Fewer Problems Than Those in Foster Homes 2Health News:Vaccine May Boost Survival of Brain Cancer Patients 2Health News:Vaccine May Boost Survival of Brain Cancer Patients 3
... Predictor Test is a qualitative, one-step, ... Follicle Stimulating Hormone (FSH) in urine ... changes related to the symptoms associated ... The FHS Menopause Predictor Test is ...
Serim PyloriTek Test Kit detects urease activity in gastric biopsy specimens for the presumptive identification of an Helicobacter pylori infection....
Immunoassay for rapid, qualitative detection of IgG antibodies specific to Helicobacter pylori in whole blood....
... The Accutest H. pylori ... test for the qualitative detection ... Helicobacter pylori in human whole ... intended as an aid in ...
Medicine Products: